Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency confirms no additional clinical data required to pursue label expansion of FUROSCIX into chronic[…]

BURLINGTON, Mass. , Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Generated net FUROSCIX® revenue of $1.6 million Ended Q2 2023 with cash, cash equivalents and short-term investments o f  $102.9 million Company to host investor conference call and webcast today, Thursday, August 10 , at 4:30pm ET BURLINGTON, Mass. , Aug.[…]

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , Aug. 03, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient[…]

Company also announces issuance of key patents covering development of alternate formulations of furosemide BURLINGTON, Mass. , Aug. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the[…]

BURLINGTON, Mass. , July 19, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare[…]

BURLINGTON, Mass. , June 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

BURLINGTON, Mass. , May 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Announced launch and commercial availability of FUROSCIX® on February 20 th Generated net FUROSCIX revenue of $2.1 million Ended Q1 2023 with cash, cash equivalents and short-term investments o f  $116.1 million Company to host investor conference call and webcast today, Wednesday, May 10 , at[…]

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , May 02, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care,[…]

Announced launch and commercial availability of FUROSCIX ® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure Ended Q4 with cash, cash equivalents, restricted cash and investments o f  $118.4M[…]

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , March 15, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient[…]

BURLINGTON, Mass. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

BURLINGTON, Mass. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced the launch and[…]

BURLINGTON, Mass. , Feb. 06, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare[…]

BURLINGTON, Mass. , Jan. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]

Commercial launch planned for February 20, 2023 BURLINGTON, Mass. , Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce[…]